mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease that exhibits constitutive activation of phosphoinositide 3-kinase (PI3K) driven by chronic B-cell receptor signaling or PTEN deficiency. Since pan-PI3K inhibitors cause severe side effects, we investigated the anti-lymphoma efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wendan, Berning, Philipp, Erdmann, Tabea, Grau, Michael, Bettazová, Nardjas, Zapukhlyak, Myroslav, Frontzek, Fabian, Kosnopfel, Corinna, Lenz, Peter, Grondine, Michael, Willis, Brandon, Lynch, James T., Klener, Pavel, Hailfinger, Stephan, Barry, Simon T., Lenz, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883168/
https://www.ncbi.nlm.nih.gov/pubmed/36352190
http://dx.doi.org/10.1038/s41375-022-01749-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883168/
https://www.ncbi.nlm.nih.gov/pubmed/36352190
http://dx.doi.org/10.1038/s41375-022-01749-0

Ejemplares similares